Cardiometabolic Effects of Apremilast in Patients With Psoriatic Arthritis: A Prospective Cohort Study
This study demonstrates that apremilast reduces fat mass in patients with PsA and suggests beneficial CV and metabolic effects, potentially reducing the risk of CV events.
Authors
- Romy Hansildaar
- Maaike Heslinga (ORCID: https://orcid.org/0000-0002-3283-3969)
- Eva H. van Geel
- Arno W. R. van Kuijk (ORCID: https://orcid.org/0000-0002-5893-0601)
- Reinhard Bos (ORCID: https://orcid.org/0000-0003-1094-5596)
- Fatih Çoban (ORCID: https://orcid.org/0000-0002-0432-1069)
- Michael Twahier Nurmohamed (ORCID: https://orcid.org/0000-0002-6274-1934)
- Mies A. Korteweg (ORCID: https://orcid.org/0000-0002-5110-3910)
- Bas Dijkshoorn (ORCID: https://orcid.org/0009-0001-1698-5647)
Institutions
- Medisch Centrum Leeuwarden (NL)
- Amsterdam UMC Location University of Amsterdam (NL)
- Reade (NL)
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
- Center for Rheumatology (US)
- Vrije Universiteit Amsterdam (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2025-02-15
- DOI
- https://doi.org/10.3899/jrheum.2024-0791
- Citations
- 3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 2.39
Funders
- Amgen
- Celgene